Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Beigene Ltd ADR (BGNE)
Beigene Ltd ADR (BGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,770,904
  • Shares Outstanding, K 95,692
  • Annual Sales, $ 1,416 M
  • Annual Income, $ -2,004 M
  • 60-Month Beta 0.79
  • Price/Sales 15.16
  • Price/Cash Flow N/A
  • Price/Book 5.68
Trade BGNE with:

Options Overview Details

View History
  • Implied Volatility 39.30% ( -0.31%)
  • Historical Volatility 35.71%
  • IV Percentile 1%
  • IV Rank 0.59%
  • IV High 98.87% on 06/14/22
  • IV Low 38.94% on 06/07/23
  • Put/Call Vol Ratio 0.04
  • Today's Volume 365
  • Volume Avg (30-Day) 82
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 1,716
  • Open Int (30-Day) 2,291

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -3.34
  • Number of Estimates 4
  • High Estimate -2.74
  • Low Estimate -3.59
  • Prior Year -5.56
  • Growth Rate Est. (year over year) +39.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
212.34 +1.74%
on 06/06/23
246.82 -12.47%
on 05/10/23
-29.64 (-12.06%)
since 05/09/23
3-Month
210.32 +2.72%
on 04/03/23
272.49 -20.72%
on 04/13/23
-1.95 (-0.89%)
since 03/09/23
52-Week
124.46 +73.58%
on 10/11/22
280.62 -23.01%
on 01/20/23
+65.40 (+43.41%)
since 06/09/22

Most Recent Stories

More News
Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's...

BGNE : 216.04 (-0.47%)
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA (zanubrutinib),...

BGNE : 216.04 (-0.47%)
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the first quarter 2023, recent business highlights, and upcoming milestones....

BGNE : 216.04 (-0.47%)
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will present data from its broad solid tumor and hematology portfolio at the upcoming American Society of Cancer Oncology...

BGNE : 216.04 (-0.47%)
3 Top Biotech Stocks Defying the Bear Market

All three companies have therapies with strong sales potential.

BIIB : 308.88 (+1.31%)
LLY : 446.04 (+0.09%)
NVS : 100.93 (+0.28%)
RHHBY : 39.1500 (-0.63%)
TGTX : 27.46 (-5.24%)
VKTX : 24.27 (-2.10%)
BGNE : 216.04 (-0.47%)
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance (ESG) goals today, including targets related to carbon emissions...

BGNE : 216.04 (-0.47%)
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its primary endpoint of overall survival, with tislelizumab in combination...

BGNE : 216.04 (-0.47%)
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s...

BGNE : 216.04 (-0.47%)
SWTX : 27.25 (+0.33%)
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b...

BGNE : 216.04 (-0.47%)
SWTX : 27.25 (+0.33%)
BeiGene Expands Presence in Latin America With Opening of Brazil Office

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the first major step in the company’s expansion in Latin America (LATAM) with the formal opening of its...

BGNE : 216.04 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

See More

Key Turning Points

3rd Resistance Point 222.80
2nd Resistance Point 221.05
1st Resistance Point 218.54
Last Price 216.04
1st Support Level 214.28
2nd Support Level 212.53
3rd Support Level 210.02

See More

52-Week High 280.62
Fibonacci 61.8% 220.97
Last Price 216.04
Fibonacci 50% 202.54
Fibonacci 38.2% 184.11
52-Week Low 124.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar